search
Back to results

A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

Primary Purpose

Intermittent Claudication

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Cilostazol
Sponsored by
Otsuka Frankfurt Research Institute GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intermittent Claudication

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. healthy male and female subjects of Caucasian race
  2. able to read, to write and to fully understand German language
  3. having given voluntary written informed consent before first invasive screening examination procedure
  4. aged 18 to 45 years, inclusive
  5. BMI of 18 - 28 kg/m2
  6. good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG, serum/urine biochemistry and hematology)

Exclusion Criteria:

  1. clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) drug hypersensitivity
  2. known hypersensitivity to one of the IMP substances
  3. severe digestive disorder or surgery of the digestive tract (except for appen¬dectomy)
  4. clinically relevant renal disorders (albuminuria, chronic infections)
  5. clinically relevant hepatic disorders
  6. clinically relevant respiratory disorders
  7. clinically relevant cardiovascular disorders, especially any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, or a history of additional risk factors for torsades de pointes (TdP) (e.g. heart failure, hypokalemia, congenital long QT-syndrome)
  8. diabetes mellitus and thyroid dysfunction or other endocrine disorders
  9. malignancy
  10. substance abuse or addiction (alcohol, illicit drugs) in the past 3 years
  11. neurologic or psychiatric illness
  12. known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6 month) haemorrhagic stroke, surgery within the previous three months, proliferative diabetic retinopathy, poorly controlled hypertension)

Sites / Locations

  • AAIPharma Deutschland GmbH & Co. KG

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Experimental

Active Comparator

Arm Label

A

B

C

D

Arm Description

Intake of Pletal 100 mg tablets dose together with 200 ml water

Intake of Pletal 100 mg ODT dose without water

Intake of Pletal 100 mg ODT dose together with 200 ml water

Intake of Pletal 100 mg ODT dose without water

Outcomes

Primary Outcome Measures

Area under the curve, maximal concentration (Cmax)

Secondary Outcome Measures

Time of maximum (tmax), Vss/f, CL/f)

Full Information

First Posted
October 15, 2008
Last Updated
September 8, 2011
Sponsor
Otsuka Frankfurt Research Institute GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT00773630
Brief Title
A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
December 2008 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Otsuka Frankfurt Research Institute GmbH

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this trial is to test whether Pletal ODT administered without water can be considered bioequivalent to Pletal administered with 200 ml water (both treatments being administered after fasting and at least 30 minutes prior to receiving a light breakfast) based on the standard pharmacokinetic variables. The secondary objective is to assess the effect of water and the effect of food on the administration of Pletal ODT based on standard pharmacokinetic variables.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intermittent Claudication

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Description
Intake of Pletal 100 mg tablets dose together with 200 ml water
Arm Title
B
Arm Type
Experimental
Arm Description
Intake of Pletal 100 mg ODT dose without water
Arm Title
C
Arm Type
Experimental
Arm Description
Intake of Pletal 100 mg ODT dose together with 200 ml water
Arm Title
D
Arm Type
Active Comparator
Arm Description
Intake of Pletal 100 mg ODT dose without water
Intervention Type
Drug
Intervention Name(s)
Cilostazol
Intervention Description
100 mg Cilostazol
Primary Outcome Measure Information:
Title
Area under the curve, maximal concentration (Cmax)
Time Frame
1-2 months
Secondary Outcome Measure Information:
Title
Time of maximum (tmax), Vss/f, CL/f)
Time Frame
1-2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy male and female subjects of Caucasian race able to read, to write and to fully understand German language having given voluntary written informed consent before first invasive screening examination procedure aged 18 to 45 years, inclusive BMI of 18 - 28 kg/m2 good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG, serum/urine biochemistry and hematology) Exclusion Criteria: clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) drug hypersensitivity known hypersensitivity to one of the IMP substances severe digestive disorder or surgery of the digestive tract (except for appen¬dectomy) clinically relevant renal disorders (albuminuria, chronic infections) clinically relevant hepatic disorders clinically relevant respiratory disorders clinically relevant cardiovascular disorders, especially any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, or a history of additional risk factors for torsades de pointes (TdP) (e.g. heart failure, hypokalemia, congenital long QT-syndrome) diabetes mellitus and thyroid dysfunction or other endocrine disorders malignancy substance abuse or addiction (alcohol, illicit drugs) in the past 3 years neurologic or psychiatric illness known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6 month) haemorrhagic stroke, surgery within the previous three months, proliferative diabetic retinopathy, poorly controlled hypertension)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Margarete Mueller, Dr.
Organizational Affiliation
AAIPharma Deutschland GmbH & Co. KG
Official's Role
Principal Investigator
Facility Information:
Facility Name
AAIPharma Deutschland GmbH & Co. KG
City
Neu-Ulm
ZIP/Postal Code
89231
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

We'll reach out to this number within 24 hrs